Global Pharmaceutical Grade Anhydrous Crystalline Glucose Market Strategic Research Report

Scope of the Report

The global Pharmaceutical Grade Anhydrous Crystalline Glucose market size is predicted to grow from US$ 512 million in 2025 to US$ 638 million in 2032; it is expected to grow at a CAGR of 3.1% from 2026 to 2032.

In 2025, global sales of pharmaceutical grade anhydrous crystalline glucose reached 731,000 tons, with an average price of US$715 per ton.

Pharmaceutical grade anhydrous crystalline glucose refers to α-D-anhydrous glucose (C₆H₁₂O₆) that meets the standards of the Chinese Pharmacopoeia (ChP), United States Pharmacopoeia (USP), or European Pharmacopoeia (EP), with a purity ≥99.8% (dry basis), moisture ≤1.0%, and strict control over bacterial endotoxins (typically <0.25 EU/g) and microbial limits. Its key quality characteristics lie in the chemical stability derived from the absence of crystallization (non-degradable by high-temperature sterilization) and precise osmolality calculation (no additional moisture interference), making it the preferred excipient for biopharmaceutical formulations and sterile injectables.

Pharmaceutical-grade anhydrous crystalline glucose uses pharmaceutical-grade corn starch that meets pharmacopoeia standards as the main raw material (accounting for 60-70% of the total cost, requiring control of heavy metals <5ppm, pesticide residues, and TSE/BSE risks). After saccharification using a dual-enzyme method (high-purity food-grade α-amylase and saccharifying enzyme), it is dehydrated through high-temperature crystallization (70-80°C) or spray drying, and further refined through ultrafiltration to remove endotoxins, deep decolorization with activated carbon, and 0.22μm terminal filtration. The packaging material must use sterile double-layer PE bags with aluminum foil lining (meeting PIC/S GMP airtightness requirements). In terms of cost structure, due to the need to meet the stringent quality control systems of USP/EP/ChP (endotoxin <0.25 EU/g, microbial limit 10²-10³ CFU/g, purity ≥99.8%), refining and testing costs account for 15-20% of the total cost (far higher than the 5-8% for food-grade). Energy consumption increases by 20-30% due to the high-temperature dehydration process compared to monohydrate, and packaging must be carried out in a Class D or Class C clean environment. All these factors combined result in pharmaceutical-grade anhydrous glucose being 2-3 times more expensive than food-grade. The main cost increases are attributed to raw material premiums (pharmaceutical-grade starch is 10-15% more expensive than ordinary starch), aseptic packaging (5-8%), and compliance certification costs (each batch requires full testing for bacteria, endotoxins, sterility, and heavy metals).

Global key Pharmaceutical Grade Anhydrous Crystalline Glucose players cover Cargill, ADM, Ingredion, Tereos, Roquette, etc.

Key Questions Addressed in this Report

What is the 10-year outlook for the global Pharmaceutical Grade Anhydrous Crystalline Glucose market?

What factors are driving Pharmaceutical Grade Anhydrous Crystalline Glucose market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Pharmaceutical Grade Anhydrous Crystalline Glucose market opportunities vary by end market size?

How does Pharmaceutical Grade Anhydrous Crystalline Glucose break out by Type, by Application?

This report presents a comprehensive overview of the global Pharmaceutical Grade Anhydrous Crystalline Glucose market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• Sterile Injection Grade
• Low Endotoxin Grade
• Cell Culture Grade
• Other

Segment by Particle Size

• Crystallic Granules
• Powder
• Ultrafine Powder

Segment by Crystal Form

• α-D-Anhydrous Glucose
• β-D-Anhydrous Glucose

Segment by Application

• Large Volume Injections
• Biopharmaceuticals and Lyophilization Technology
• Cell and Gene Therapy
• Other

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Pharmaceutical Grade Anhydrous Crystalline Glucose market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Large Volume Injections, Biopharmaceuticals and Lyophilization Technology, Cell and Gene Therapy evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact